Danaher: Robust Q4 Beat and Credible 2026 Growth Outlook Underpin Buy Rating

William Blair analyst Matt Larew has maintained their bullish stance on DHR stock, giving a Buy rating on January 20.

Matt Larew has given his Buy rating due to a combination of factors that underscore Danaher’s solid operating performance and favorable outlook. The company’s fourth-quarter results exceeded both his and the Street’s expectations on revenue, with core growth coming in ahead of prior estimates across biotechnology, life sciences, and diagnostics. Margin performance was also slightly better than projected, indicating disciplined cost control and resilience despite a modest year-over-year decline. In particular, the biotechnology segment showed healthy core growth, supported by robust bioprocessing demand, which Larew views as a key long-term value driver.

Larew also highlights the credibility and attractiveness of management’s 2026 guidance, which calls for 3%–6% core revenue growth, with biotechnology expected to grow at a high-single-digit pace. This outlook suggests that current business momentum, especially in higher-growth, higher-margin areas, can be sustained over the medium term. While life sciences and diagnostics are expected to be more muted in the near term, the forecast for stabilization and a gradual pickup supports a positive multi-year narrative. Taken together, the better-than-expected quarter, solid segment trends, and reaffirmed growth framework provide the foundation for Larew’s positive stance on the stock.

Larew covers the Healthcare sector, focusing on stocks such as AptarGroup, MaxCyte, and Option Care Health. According to TipRanks, Larew has an average return of -0.1% and a 49.40% success rate on recommended stocks.

In another report released on January 20, Morgan Stanley also maintained a Buy rating on the stock with a $270.00 price target.